Skip to main content

PHG · Koninklijke Philips NV

Track PHG — free
$29.79 -0.11 (-0.35%)
Market Cap
$29.22B
Shares
977.61M
Volume · Nov 18 674.48K Avg daily vol (3M) 1.14M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.89 Open$29.83 Day$29.83–30.08 52W close$23.81–32.91 Avg vol 30d1.5M Short int2.1M · 0.2% of shares · 1.7d Short vol51% Last earningsNov 3, 2026 DataJan 2020–Nov 2026

Up next

Feb 9, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 3
Earnings call
Margin beats expectations despite legal provision

Q3 order intake rose 8%, comparable sales grew approximately 3%, and adjusted EBITDA margin increased by 70 basis points to 13%. Philips generated 384 million euros of free cash flow and recorded a 288 million euros Respironics provision.

Read from the first part of this long document
5 source passages
Let me start with an overview of our Q3 performance. We delivered an excellent order intake growth of 8%, driven by sustained customer demand and further traction from our recently launched innovations. Comparable sales grew approximately 3%, driven by strength in personal health and connected care. Adjusted EBITDA margin increased by 70 basis points to 13% ahead of our expectations. Free cash flow was a strong inflow of 384 million euros. As a result, Philips recorded a provision of 288 million euros. Open the document at this passage
Nov 3
Current report 6-K
Q3 growth and Respironics settlement progress

Royal Philips reported Q3 comparable sales growth of 3% and order intake growth of 8%. Respironics reached agreement in principle with the US Department of Justice, triggering a EUR 288 million provision; the 2026 outlook was reiterated.

5 source passages
Q3 2026 Group performance •Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment •Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027. Philips reiterates its full-year 2026 outlook: Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-1.0%
Year over year
Operating margin
8.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
3.4%
Trailing 12 months
Shares change YoY
+4.1%
Year over year · more shares
Price change (1Y)
+6.8%
Trailing year
Short interest
0.2%
Latest settlement · 1.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +14%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 67%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +15%
trailing
6-month return +13%
trailing
YTD return +10%
this year
Relative strength +16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $26 › 200d $27 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.21% of shares out · ▼ -25.6% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
344 holders — mid 3-yr range
Squeeze score 40
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −28%
past year
ATR 2.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 6, 2026
Comparable sales growth · full year 2026 3% – 4.5%
Adjusted EBITDA margin · full year 2026 Non-GAAP 12.5% – 13%
Previous outlook earlier release · from the Earnings Call filed Sep 30, 2025

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA margin · full year 11.3% – 11.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
67% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $26 › 200d $27 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.21% of shares out · ▼ -25.6% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
344 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $24 Now $30 · 67% Range high $33
vs 200-day avg +10% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PHG
Koninklijke Philips NV
this stock
$29.22B +10.4% — — 0.2%
ABT
Abbott Laboratories
$181.35B -16.4% +5.7% 39.1 1.1%
MDT
Medtronic plc
$130.88B +6.5% +8.4% 25.2 1.8%
SYK
Stryker Corp
$120.88B -9.7% +11.2% 33.8 1.7%
BSX
Boston Scientific Corp
$62.37B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
344
% held
5.4%
Net QoQ
+1.6M sh
Top holder
Mondrian Investment Partn…
Held Float
View
Held by Funds
Fund positions
43
View
Short & Settlement
Short Interest Falling
Shares short
2.1M
Days to cover
1.7d
Change
-714.3K sh
View
Short Volume
Short vol %
51%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.8K
Value
$48.3K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
34.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 3, 2026
This year
11

Royal Philips reported Q3 comparable sales growth of 3% and order intake growth of 8%. Respironics reached agreement in principle with the US Department of Justice, triggering a EUR 288 million provision; the 2026 outlook was reiterated.

View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Philips to nominate Dick Boer, La…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
PHG -1.7% +15.0% +13.0% +11.0% +10.4%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +0.6% +19.7% +16.0% +14.1% +3.0%

Capital returns

Latest dividend
$1.013 / share · ex May 13, 2026
Raised 4.8%
Paid (TTM)
$1.013 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 313216 CUSIP 500472303 13F (30d) 365 filings 310 filers Visit website Investor relations